medigraphic.com
ISSN 0016-3813 (Print)

2009, Number 2

<< Back Next >>

Gac Med Mex 2009; 145 (2)

Incremento del glutamato en el estriado de asociación en esquizofrenia. Resultados preliminares de un estudio longitudinal con espectroscopia con resonancia magnética

Fuente-Sandoval C, Favila R, Alvarado P, León-Ortiz P, Díaz-Galvis L, Amezcua C, García-Muñoz E, Graff-Guerrero A

Language: Spanish
References: 55
Page: 109-113
PDF size: 92.43 Kb.


ABSTRACT

Objective: To compare glutamate levels (Glu) found in the dorsalcaudate nucleus (a dopamine rich region) and in the cerebellum (a low dopamine region) among: 1) schizophrenia patients undergoing an acute psychotic episode, 2) after receiving antidopaminergic treatment (Risperidone), and 3) healthy controls.
Methods: Fourteen drug-free patients with schizophrenia and fourteen healthy controls were included. Patients underwent two proton magnetic resonance spectroscopy (1H-MRS) studies, one prior to treatment and the second after 6-weeks of daily Risperidone treatment. Controls underwent one 1H-MRS study. Glutamate levels were normalized according to the relative concentration of Creatine (Cr).
Results: The dorsal-caudate nucleus among schizophrenia patients showed higher levels of Glu/Cr during the drug-free condition (t=-2.16, p=0.03) and after antipsychotic treatment (t=2.12, p=0.04) compared with controls. No difference was observed in the cerebellum between the drug-free, post-treatment and controls conditions.
Conclusions: Our results suggest that the Glu increase observed in the dorsal-caudate in schizophrenia is illness-mediated and does not change after 6-weeks of antipsychotic treatment. Moreover, the lack of change detected in the cerebellum suggests that the Glu increase in schizophrenia is not ubiquitous within the brain and that may be associated with dopamine target regions.


REFERENCES

  1. American Psychiatric Association. The Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. 4th ed. Washington, DC: American Psychiatric Association; 2000.

  2. Kirkbride JB, Fearon P, Morgan C, Dazzan P, Morgan K, Tarrant, J, et al. Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AeSOP study. Arch Gen Psychiatry 2006;63:250-258.

  3. Owen MJ, Craddock N, Jablensky A. The genetic deconstruction of psychosis. Schizophr Bull 2007;33:905-911.

  4. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223.

  5. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007;13:1102-1107.

  6. David HN, Ansseau M, Abraini JH. Dopamine-glutamate reciprocal modulation of release and motor responses in the rat caudate-putamen and nucleus accumbens of “intact” animals. Brain Res Brain Res Rev 2005;50:336-360.

  7. Cepeda C, Levine MS. Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum. Dev Neurosci 1998;20:1-18.

  8. Levine MS, Cepeda C. Dopamine modulation of responses mediated by excitatory amino acids in the neostriatum. Adv Pharmacol 1998;42:724-729.

  9. Kulagina NV, Zigmond MJ, Michael AC. Glutamate regulates the spontaneous and evoked release of dopamine in the rat striatum. Neuroscience 2001;102:121-128.

  10. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 1998;155:761-767.

  11. Sato M. A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis. Ann N Y Acad Sci 1992;654:160-170.

  12. Sato M, Numachi Y, Hamamura T. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophr Bull 1992;18:115-122.

  13. Laruelle M, Abi-Dargham A, Van Dyck CH, Gil R, D’Souza CD, Erdos J, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996;93:9235-9240.

  14. Hietala J, Syvalahti E, Vilkman H, Vuorio K, Rakkolainen V, Bergman J, et al. Depressive symptoms and presynaptic dopamine function in neurolepticnaive schizophrenia. Schizophr Res 1999;35:41-50.

  15. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 2003;160:13-23.

  16. Huttunen J, Heinimaa M, Svirskis T, Nyman M, Kajander J, Forsback S, et al. Striatal dopamine synthesis in first-degree relatives of patients with schizophrenia. Biol Psychiatry 2008;63:114-117.

  17. Jensen J, Willeit M, Zipursky RB, Savina I, Smith AJ, Menon M, et al. The formation of abnormal associations in schizophrenia: neural and behavioral evidence. Neuropsychopharmacology 2008;33:473-479.

  18. Carlsson M, Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia—implications for schizophrenia and Parkinson’s disease. Trends Neurosci 1990;13:272-276.

  19. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-1308.

  20. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995;52:998-1007.

  21. Kegeles LS, Martinez D, Kochan LD, Hwang DR, Huang Y, Mawlawi O, et al. NMDA antagonist effects on striatal dopamine release: Positron emission tomography studies in humans. Synapse 2002;43:19-29.

  22. Breier A, Adler CM, Weisenfeld N, et al. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 1998;29:142-147.

  23. Aalto S, Hirvonen J, Scheinin H, Någren K, Vilkman H, Hietala J, et al. Ketamine does not decrease striatal dopamine D2 receptor binding in man. Psychopharmacology 2002;164:401-406. Epub 2002 Oct 12.

  24. Aalto S, Ihalainen J, Hirvonen J, Kajander J, Scheinin H, Tanila H, et al. Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology 2005;182:375-383.

  25. Di Costanzo A, Trojsi F, Tosetti M, Giannatempo GM, Nemore F, Piccirillo M, et al. High-field proton MRS of human brain. Eur J Radiol 2003;48:146-153.

  26. Di Costanzo A, Trojsi F, Tosetti M, Schirmer T, Lechner SM, Popolizio T, et al. Proton MR spectroscopy of the brain at 3 T: an update. Eur Radiol 2007;17:1651-1662.

  27. Theberge J, Al-Semaan Y, Williamson PC, Menon RS, Neufeld RW, Rajakumar N, et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry 2003;160:2231-2233.

  28. Van Elst LT, Valerius G, Buchert M, Thiel T, Rusch N, Bubl E, et al. Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol Psychiatry 2005;58:724-730.

  29. Purdon SE, Valiakalayil A, Hanstock CC, Seres P, Tibbo P. Elevated 3T proton MRS glutamate levels associated with poor Continuous Performance Test (CPT-0X) scores and genetic risk for schizophrenia. Schizophr Res 2008;99:218-224.

  30. Graff-Guerrero A, Willeit M, Ginovart N, Mamo D, Mizrahi R, Rusjan P, et al. Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans. Hum Brain Mapp 2008;29:400-410.

  31. Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 2001;21:1034-1057.

  32. Friedman SD, Stidley CA, Brooks WM, Hart BL, Sibbitt WL, Jr. Brain injury and neurometabolic abnormalities in systemic lupus erythematosus. Radiology 1998;209:79-84.

  33. Meyerhoff DJ, MacKay S, Bachman L, Poole N, Dillon WP, Weiner MW, et al. Reduced brain N-acetylaspartate suggests neuronal loss in cognitively impaired human immunodeficiency virus-seropositive individuals: in vivo 1H magnetic resonance spectroscopic imaging. Neurology 1993;43:509-515.

  34. Giroud M, Walker P, Bernard D, Lemesle M, Martin D, Baudouin N, et al. Reduced brain N-acetyl-aspartate in frontal lobes suggests neuronal loss in patients with amyotrophic lateral sclerosis. Neurol Res 1996;18:241-243.

  35. First MB, Spitzer RL, Williams JB, Gibbon M. Structured Clinical Interview for DSM-IV Disorders (SCID). Washington, DC: American Psychiatric Association; 1997.

  36. Fresan A, De la Fuente-Sandoval C, Loyzaga C, Garcia-Anaya M, Meyenberg N, Nicolini H, et al. A forced five-dimensional factor analysis and concurrent validity of the Positive and Negative Syndrome Scale in Mexican phrenic patients. Schizophr Res 2005;72:123-129.

  37. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.

  38. Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed 2001;14:260-264.

  39. Bustillo JR, Rowland LM, Jung R, Brooks WM, Qualls C, Hammond R, et al. Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia. Neuropsychopharmacology 2008;33:2456-2466.

  40. Brodal P. The central nervous system : structure and function. 3rd ed. Oxford; New York: Oxford University Press; 2004.

  41. Farde L, Wiesel FA, Halldin C, Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988;45:71-76.

  42. Lehericy S, Ducros M, Krainik A, Francois C, Van de Moortele PF, Ugurbil K, et al. 3-D diffusion tensor axonal tracking shows distinct SMA and pre-SMA projections to the human striatum. Cereb Cortex 2004;14:1302-1309.

  43. De Keyser J, Claeys A, De Backer JP, Ebinger G, Roels F, Vauquelin G. Autoradiographic localization of D1 and D2 dopamine receptors in the human brain. Neurosci Lett 1988;91:142-147.

  44. Camps M, Cortes R, Gueye B, Probst A, Palacios JM. Dopamine receptors in human brain: Autoradiographic distribution of D2 sites. Neuroscience 1989;28:275.

  45. Ginovart N, Willeit M, Rusjan P, Graff A, Bloomfield PM, Houle S, et al. Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain. J Cereb Blood Flow Metab 2007;27:857-871.

  46. Dum RP, Strick PL. An unfolded map of the cerebellar dentate nucleus and its projections to the cerebral cortex. J Neurophysiol 2003;89:634-639.

  47. Middleton FA, Strick PL. Cerebellar projections to the prefrontal cortex of the primate. J Neurosci 2001;21:700-712.

  48. Schmahmann JD, Pandya DN. Prefrontal cortex projections to the basilar pons in rhesus monkey: implications for the cerebellar contribution to higher function. Neurosci Lett 1995;199:175-178.

  49. Kelly RM, Strick PL. Cerebellar loops with motor cortex and prefrontal cortex of a nonhuman primate. J Neurosci 2003;23:8432-8444.

  50. Steen RG, Hamer RM, Lieberman JA. Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology 2005;30:1949-1962.

  51. Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989;244:1360-1362.

  52. Bartha R, Williamson PC, Drost DJ, Malla A, Carr TJ, Cortese L, et al. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 1997;54:959-965.

  53. Olbrich HM, Valerius G, Rusch N, Buchert M, Thiel T, Hennig J, et al. Frontolimbic glutamate alterations in first episode schizophrenia: evidence from a magnetic resonance spectroscopy study. World J Biol Psychiatry 2008;9:59-63.

  54. Maton B, Londono A, Sawrie S, Knowlton R, denHollander J, Kuzniecky R. Reproducibility of proton magnetic resonance spectroscopy imaging measurements of normal human hippocampus at 1.5 T: clinical implications. J Neuroimaging 2001;11:194-201.

  55. Brooks WM, Friedman SD, Stidley CA. Reproducibility of 1H-MRS in vivo. Magn Reson Med 1999;41:193-197.




2020     |     www.medigraphic.com